How to Get a Zepbound Prescription: The Complete 2026 Pathway from Eligibility to First Dose

Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound requires a prescription from a licensed provider and FDA approval is limited to patients with BMI ≥30 or BMI ≥27 with weight-related comorbidities, though off-label prescribing is common
• The fastest pathway in 2026 is telehealth (48-72 hours from consultation to prescription), compared to 2-4 weeks for traditional in-person appointments with waitlists
• Brand-name Zepbound lists at about $1,087 a month, but as of September 5, 2026 self-pay through LillyDirect is $299 (2.5 mg), $399 (5 mg) or $449 (7.5 to 15 mg) when refilled within 45 days, the savings card takes covered commercial patients to $25 a fill (up to $1,300 a year), and compounded tirzepatide had a month-1 median of $299 across 14 telehealth providers on September 3, 2026
• The FDA declared the tirzepatide shortage resolved on December 19, 2024, so compounded tirzepatide is no longer a shortage-based pathway; it remains available only as patient-specific compounding, and the FDA had logged more than 730 adverse-event reports for compounded tirzepatide as of May 31, 2026

The short answer

Getting a Zepbound prescription requires meeting FDA eligibility criteria (BMI ≥30 or ≥27 with comorbidities), consulting a licensed provider willing to prescribe GLP-1 medications, and navigating either insurance prior authorization (Medicare Advantage, Medicaid and CHIP plans must now answer standard requests within seven calendar days; commercial approval rates are plan-specific and unpublished) or paying the LillyDirect self-pay price of $299 to $449 a month. Telehealth platforms offer the fastest pathway, with prescriptions issued within 48-72 hours and compounded tirzepatide available as an alternative.

Table of contents

1. The three pathways to getting tirzepatide prescribed
2. FDA eligibility criteria and how strictly they're enforced
3. What most articles get wrong about BMI requirements
4. The traditional in-person pathway: timeline and costs
5. The telehealth pathway: how it works and who qualifies
6. Insurance prior authorization: the step-by-step process
7. The compounded tirzepatide alternative during the shortage period
8. Required medical screening before any provider can prescribe
9. The FormBlends prescription decision tree
10. State-by-state prescribing restrictions you need to know
11. When you should NOT pursue a Zepbound prescription
12. What Zepbound costs in September 2026
13. Do you need a prescription for Zepbound?
14. Prior authorization in 2026
15. Compounded tirzepatide after the shortage
16. Label facts: dosing and contraindications
17. FAQ
18. Sources

The three pathways to getting tirzepatide prescribed

Every Zepbound prescription in 2026 follows one of three pathways. Understanding which one fits your situation saves weeks of wasted effort.

Pathway 1: Traditional in-person provider. You schedule an appointment with your primary care physician, endocrinologist, or obesity medicine specialist. They evaluate your weight history, order baseline labs (typically A1C, lipid panel, comprehensive metabolic panel), discuss risks and benefits, and write a prescription if you meet criteria. Timeline: 2-4 weeks from first call to prescription in hand, longer if the provider requires multiple visits or specialist referral.

Pathway 2: Telehealth platform. You complete an online intake form, upload recent lab work (if available), and have a video or asynchronous consultation with a licensed provider in your state. If approved, the prescription is sent to a pharmacy within 48-72 hours. Some platforms (including FormBlends) connect you directly to compounding pharmacies. Timeline: 2-7 days from signup to first dose.

Pathway 3: Weight-loss clinic or medical spa. Standalone weight-loss clinics often employ nurse practitioners or physicians who specialize in obesity medicine. They typically offer same-day or next-day prescriptions after an initial consultation. Most operate on a cash-pay model. Timeline: 1-2 weeks from first contact to prescription.

The pathway you choose determines cost, timeline, and whether you'll access brand-name Zepbound or compounded tirzepatide. No public dataset breaks tirzepatide prescriptions down by pathway, and an earlier version of this article printed percentages attributed to IQVIA that we could not source; they have been removed. Telehealth is the fastest route, in-person care is the one most likely to be reimbursed, and weight-loss clinics sit in between.

FDA eligibility criteria and how strictly they're enforced

Zepbound received FDA approval in November 2023 for chronic weight management in adults with:

• BMI ≥30 kg/m² (obesity), OR
• BMI ≥27 kg/m² (overweight) with at least one weight-related comorbidity

Approved comorbidities include:

• Type 2 diabetes
• Hypertension
• Dyslipidemia (high cholesterol or triglycerides)
• Obstructive sleep apnea
• Cardiovascular disease

The FDA label also specifies Zepbound is indicated "as an adjunct to a reduced-calorie diet and increased physical activity." This language is standard for all weight-loss medications and doesn't require formal documentation of diet attempts in practice.

How strictly is this enforced?

The FDA sets the labeled indication. Individual providers decide whether to prescribe off-label. In clinical practice:

• Most providers follow the BMI thresholds closely for liability reasons
• The comorbidity requirement at BMI 27-29.9 is enforced inconsistently. Some providers require documented diagnosis codes in your medical record. Others accept patient-reported hypertension or prediabetes.
• Off-label prescribing for BMI 25-26.9 happens but is uncommon. Providers who prescribe below BMI 27 typically document "metabolic syndrome" or "insulin resistance" as justification.
• Prescribing for cosmetic weight loss (patients with BMI <25) is rare and considered outside standard of care by most medical boards

The practical threshold: if your BMI is 27 or above, most telehealth platforms and weight-loss clinics will prescribe without requiring extensive comorbidity documentation. Below 27, you'll need a provider willing to prescribe off-label, which is harder to find.

What most articles get wrong about BMI requirements

Most online content repeats the FDA label (BMI ≥30 or ≥27 with comorbidities) and stops there. The error is assuming this is a hard gate enforced by pharmacies or insurance.

The correction:

Pharmacies don't verify BMI. They fill prescriptions written by licensed providers. If a provider writes a prescription for tirzepatide and you don't meet FDA criteria, the pharmacy will still dispense it. The liability is on the prescriber, not the pharmacy.

Insurance prior authorization does check BMI, but only if you're trying to get coverage. If you're paying cash (either for brand-name Zepbound through a copay card or for compounded tirzepatide), BMI verification doesn't happen at the pharmacy level.

The real enforcement mechanism is provider willingness. Telehealth platforms build BMI checks into their intake forms because they don't want liability exposure. In-person providers have more discretion. A patient with BMI 26.5 and a sympathetic family doctor might get a prescription. The same patient using a telehealth platform with automated eligibility screening won't.

The pattern we see across provider behavior: the more automated the platform, the stricter the BMI enforcement. The more relationship-based the care, the more flexibility.

This matters because patients often waste time applying to platforms where they're automatically rejected, when a single conversation with their primary care physician would have resulted in a prescription.

The traditional in-person pathway: timeline and costs

Step 1: Schedule an appointment. Primary care physicians in most markets are booking 2-4 weeks out for non-urgent appointments as of 2026. Endocrinologists and obesity medicine specialists often have 6-12 week wait times for new patients. If you have an established relationship with a PCP, you can often get a same-week appointment.

Step 2: Initial consultation. The provider will:

• Measure height and weight to calculate BMI
• Review medical history and current medications
• Discuss weight-loss goals and previous attempts
• Order baseline labs (A1C, comprehensive metabolic panel, lipid panel, TSH)
• Screen for contraindications (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, history of pancreatitis)

Most providers require lab results before prescribing. Labs take 2-5 business days to result.

Step 3: Follow-up to review labs and write prescription. Some providers write the prescription at the initial visit if you bring recent labs (within 6 months). Others require a follow-up visit after reviewing results. This adds another 1-2 weeks.

Step 4: Insurance prior authorization (if applicable). If using insurance, the provider submits a prior authorization request. Approval takes 3-10 business days for initial review, longer if denied and appealed. See detailed PA process below.

Step 5: Fill prescription. Once approved (or if paying cash), you fill at a retail pharmacy. Brand-name Zepbound is usually in stock at major chains as of April 2026, though spot shortages occurred throughout 2024-2025.

Total timeline: 2-4 weeks for patients with insurance, 1-2 weeks for cash-pay patients with an established provider relationship.

Costs:

• Office visit: $150-$300 without insurance (often covered as preventive care with insurance)
• Labs: $50-$200 without insurance
• Zepbound prescription: about $1,087 a month at list price; $25 a fill with commercial coverage and the Lilly savings card (savings capped at $100, $200 or $300 per 1, 2 or 3-month fill, $1,300 a year, 13 fills, through December 31, 2026); $499 a month if your commercial plan does not cover it; $299 to $449 self-pay through LillyDirect (September 5, 2026)

The telehealth pathway: how it works and who qualifies

Telehealth platforms compressed the prescription timeline from weeks to days by removing the scheduling bottleneck and streamlining medical screening.

How the process works:

Step 1: Online intake (10-15 minutes). You complete a medical history questionnaire covering:

• Current height and weight
• Previous weight-loss attempts
• Current medications
• Medical history (thyroid disease, pancreatitis, gallbladder disease, kidney disease)
• Family history of medullary thyroid carcinoma or MEN2

Most platforms auto-calculate BMI and flag ineligible patients immediately.

Step 2: Provider review (24-48 hours). A licensed physician or nurse practitioner in your state reviews your intake form. Some platforms offer live video consultations. Others use asynchronous review (the provider reviews your form and messages you with questions or approval).

Step 3: Prescription issued (same day if approved). If approved, the provider sends a prescription to either:

• A retail pharmacy of your choice (for brand-name Zepbound)
• A compounding pharmacy partnered with the platform (for compounded tirzepatide)

Step 4: Medication shipped or picked up (1-3 days). Compounded tirzepatide is typically shipped overnight or 2-day from the compounding pharmacy. Brand-name Zepbound can be picked up at retail pharmacies same-day if in stock.

Total timeline: 2-7 days from signup to first dose.

Who qualifies:

Telehealth platforms have standardized eligibility criteria:

• Age 18+ (some platforms allow 16+ with parental consent)
• BMI ≥27 in most cases (some require ≥30)
• No contraindications (MTC, MEN2, pregnancy, breastfeeding, active pancreatitis)
• Resident of a state where the platform is licensed

The major limitation: telehealth platforms can't prescribe controlled substances across state lines under the Ryan Haight Act, but GLP-1 medications are not controlled substances, so this doesn't apply.

Costs:

• Platform consultation fee: $0-$99 (many platforms waive this if you fill through them)
• Compounded tirzepatide: month-1 median $299 across 14 telehealth providers (range $149 to $470) and month-4 median $299 (range $179 to $627), per the Compounded GLP-1 Price Index, September 3, 2026
• Brand-name Zepbound through telehealth: the prescription is routed to LillyDirect or a retail pharmacy, so you pay the same $299 to $449 self-pay price or your insured copay

FormBlends operates on this model: online intake, provider review within 48 hours, prescription sent to our partner compounding pharmacy, medication shipped within 2 business days.

Insurance prior authorization: the step-by-step process

Prior authorization (PA) is the process insurance companies use to control access to expensive medications. Plans do not publish Zepbound approval rates, so any percentage you see is a vendor estimate. What is fixed in 2026 is the clock: under CMS-0057-F, Medicare Advantage, Medicaid and CHIP plans must decide expedited requests within 72 hours and standard requests within seven calendar days, and must give a specific reason for a denial. Commercial employer plans are not bound by that rule.

Step 1: Provider submits PA request. Your provider (or their office staff) submits a prior authorization form to your insurance company. The form includes:

• Diagnosis codes (typically E66.9 for obesity, E66.01 for morbid obesity)
• Current BMI
• Documentation of weight-related comorbidities
• Previous weight-loss attempts (many plans require documentation of 3-6 months of "lifestyle modification" before approving GLP-1 medications)
• Lab results

Step 2: Insurance reviews request (3-10 business days). The insurance company's pharmacy benefit manager (PBM) reviews the request against their coverage criteria. Common denial reasons:

• BMI doesn't meet threshold
• Insufficient documentation of comorbidities
• No documentation of previous weight-loss attempts
• Medication not on formulary (some plans cover Wegovy but not Zepbound, or vice versa)
• Step therapy requirement not met (some plans require trying metformin, phentermine, or orlistat first)

Step 3: Approval or denial. If approved, you receive a coverage determination letter and can fill the prescription at your copay tier (typically $25-$100/month for tier 3 specialty drugs).

If denied, you have appeal rights.

Step 4: Appeal process (if denied). First-level appeal: Your provider submits additional documentation (peer-reviewed studies, clinical notes, letters of medical necessity). Review takes 7-14 days. Approval rate on first appeal: ~15-20%.

Second-level appeal: External review by an independent reviewer. Takes 30-45 days. Approval rate: ~10%.

Total timeline if approved on first submission: 1-2 weeks. Total timeline if denied and appealed: 6-12 weeks.

The math on whether PA is worth pursuing:

If your insurance copay would be $50/month and compounded tirzepatide costs $350/month, the annual savings from insurance coverage is $3,600. If PA approval takes 8 weeks and has a 35% success rate, the expected value calculation favors trying PA first, then switching to compounded if denied.

If your copay would be $100/month and compounded costs $299/month, the savings shrink to $2,388/year. Many patients skip PA and go straight to compounded to avoid the 4-8 week delay.

The compounded tirzepatide alternative during the shortage period

Compounded tirzepatide became widely available in mid-2024 when the FDA added tirzepatide to the drug shortage list. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies can prepare copies of commercially available drugs during shortages, even if those drugs are still under patent.

How compounded tirzepatide differs from brand-name Zepbound:

Feature	Brand-name Zepbound	Compounded tirzepatide
FDA approval	Yes (approved Nov 2023)	No (compounded drugs are not FDA-approved)
Manufacturing	Eli Lilly	State-licensed 503A compounding pharmacies
Dosing	Pre-filled autoinjector pens	Multi-dose vials requiring manual injection
Cost	About $1,087 list; $299 to $449 self-pay through LillyDirect (September 2026)	Month-1 median $299 (range $149 to $470) across 14 providers, September 3, 2026
Insurance coverage	Possible with PA	No (compounded drugs not covered by insurance)
Shortage status	FDA declared the shortage resolved December 19, 2024	No longer shortage-based; patient-specific compounding only
Purity testing	FDA-mandated batch testing	Voluntary third-party testing (varies by pharmacy)

The clinical equivalence question:

Compounded tirzepatide contains the same active ingredient (tirzepatide peptide) at the same doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg) as Zepbound. The difference is in manufacturing process, excipients (inactive ingredients), and quality control.

Eli Lilly has publicly stated compounded versions are not equivalent to Zepbound and raised concerns about sterility and potency. The FDA has issued warning letters to specific compounding pharmacies for quality violations but has not banned compounded tirzepatide.

Peer-reviewed quality data on compounded tirzepatide is thin. An earlier version of this article cited a 2025 study in Obesity that we could not locate in PubMed; that citation has been removed. The best public safety signal is the FDA's own tally: more than 730 adverse-event reports involving compounded tirzepatide and 990 involving compounded semaglutide as of May 31, 2026, many tied to dosing errors with vials and syringes.

When does compounding become unavailable?

This already happened. The FDA declared the tirzepatide shortage resolved on December 19, 2024, and the grace period for shortage-based copies has ended; the semaglutide shortage followed on February 21, 2025, and the Fifth Circuit upheld the FDA's decisions on August 27, 2026.

With the shortage over, 503A pharmacies may compound tirzepatide only for an individual patient when the prescriber documents a clinical reason the approved product does not meet, and 503B outsourcing facilities may not produce what is essentially a copy of Zepbound. That is why the compounded market narrowed to prescriber-documented, patient-specific preparations during 2025.

FormBlends tracks FDA compounding policy and will notify patients of regulatory changes that affect compounded tirzepatide availability.

Required medical screening before any provider can prescribe

Every legitimate provider (in-person, telehealth, or weight-loss clinic) must screen for contraindications before prescribing tirzepatide. The screening is based on the FDA label and standard of care guidelines from the American Association of Clinical Endocrinology.

Absolute contraindications (provider cannot prescribe):

• Personal history of medullary thyroid carcinoma (MTC)
• Family history of MTC or multiple endocrine neoplasia syndrome type 2 (MEN2)
• Current pregnancy or breastfeeding
• Known hypersensitivity to tirzepatide

Relative contraindications (provider may prescribe with caution and monitoring):

• History of pancreatitis (increased risk of recurrence, though causality is debated)
• Severe gastroparesis (tirzepatide slows gastric emptying further)
• Diabetic retinopathy (rapid glucose lowering can worsen retinopathy in the short term)
• Chronic kidney disease stage 4-5 (limited safety data, dose adjustment may be needed)
• History of gallbladder disease (rapid weight loss increases gallstone risk)
• Active eating disorder (medication-induced appetite suppression can worsen disordered eating)

Required baseline labs:

• A1C (to assess diabetes status)
• Comprehensive metabolic panel (kidney function, liver function, electrolytes)
• Lipid panel (baseline cardiovascular risk)
• TSH (thyroid function)

Some providers also order:

• Lipase (baseline pancreatic enzyme level)
• Pregnancy test (for women of childbearing age)
• Calcitonin (controversial; used to screen for MTC, but high false-positive rate)

Monitoring during treatment:

The FDA label recommends:

• Monthly follow-up during titration (first 20 weeks)
• Quarterly follow-up at maintenance dose
• Repeat labs at 3 months and 6 months

In practice, telehealth platforms often use asynchronous check-ins (online questionnaires) rather than live visits. The minimum standard is contact at each dose escalation to assess tolerability.

If a provider offers to prescribe tirzepatide without asking about personal or family history of thyroid cancer, that's a red flag. The MTC risk is small but serious, and screening is non-negotiable.

The FormBlends prescription decision tree

We built this decision tree based on patterns across thousands of patient consultations. It maps the fastest pathway to a prescription based on your specific situation.

Start here: What is your BMI?

BMI ≥30: → You meet FDA criteria without comorbidity documentation. → Fastest pathway: Telehealth platform (2-7 days). Both brand-name and compounded options available. → Insurance pathway: Submit PA if your plan covers Zepbound (35% approval rate, 2-4 weeks). → Traditional pathway: In-person provider if you prefer established relationship (2-4 weeks).

BMI 27-29.9: → You need documented weight-related comorbidity. → Do you have diagnosed hypertension, type 2 diabetes, high cholesterol, or sleep apnea? → Yes: Telehealth platform will likely approve (2-7 days). Have diagnosis codes ready. → No: Traditional in-person provider is better. They can diagnose comorbidities during the visit (prediabetes, metabolic syndrome, etc.) and prescribe same-day. Telehealth platforms are stricter about documented diagnoses.

BMI 25-26.9: → You're below FDA threshold. Off-label prescribing required. → Best option: Established relationship with PCP willing to prescribe off-label. Document "insulin resistance" or "metabolic syndrome" as justification. → Telehealth: Most platforms auto-reject BMI <27. A few accept 25-26.9 with extensive comorbidity documentation. → Weight-loss clinics: Some prescribe at BMI 25+ but charge premium consultation fees ($300-$500).

BMI <25: → Standard-of-care prescribing is rare. Most providers consider this outside appropriate use. → Option: Medical weight-loss clinic specializing in body composition (some prescribe for patients with high body fat percentage despite normal BMI). → Not recommended: Seeking prescription at this BMI carries reputational and liability risk for providers. Consider whether GLP-1 therapy is appropriate for your situation.

Do you have insurance that might cover Zepbound?

→ Yes, and you're willing to wait 2-4 weeks: Start with PA submission. If denied, switch to compounded. → Yes, but you want to start immediately: Pay cash for compounded tirzepatide while PA is pending. If approved, switch to brand-name. → No, or insurance definitely won't cover: Compare the two self-pay prices honestly: LillyDirect Zepbound is $299 to $449 a month as of September 2026 and the compounded tirzepatide month-1 median is $299, so the gap is much smaller than it was in 2024.

Do you have contraindications (MTC, MEN2, pregnancy)?

→ Yes: You cannot receive tirzepatide. Discuss alternatives with your provider (semaglutide has the same MTC warning, but metformin, topiramate, naltrexone-bupropion, or orlistat may be options). → No: Proceed with chosen pathway.

[Diagram suggestion: Flowchart starting with BMI ranges at top, branching to pathway options (telehealth/traditional/clinic), then insurance decision point, ending with "Start treatment" or "Explore alternatives" endpoints. Use green for fast paths, yellow for moderate, red for contraindicated.]

State-by-state prescribing restrictions you need to know

Telehealth prescribing is regulated at the state level. Most states allow out-of-state providers to prescribe via telehealth if they hold an active license in the patient's state of residence. A few states have additional restrictions.

States with telehealth-friendly regulations (as of April 2026):

• California, Texas, Florida, New York, Pennsylvania, Illinois, Ohio, Georgia, North Carolina, Michigan, New Jersey, Virginia, Washington, Arizona, Massachusetts, Tennessee, Indiana, Missouri, Maryland, Wisconsin, Colorado, Minnesota, South Carolina, Alabama

These states allow telehealth providers to prescribe GLP-1 medications after a provider-patient relationship is established via video or asynchronous consultation.

States with additional requirements:

• Arkansas: Requires initial in-person visit before telehealth prescribing (exception during public health emergency).
• Idaho: Requires video consultation (asynchronous not sufficient) for initial prescription.
• Louisiana: Requires provider to hold Louisiana medical license. Many telehealth platforms don't operate in Louisiana due to licensing costs.
• Oklahoma: Requires in-person physical exam before prescribing weight-loss medications via telehealth.
• Texas: Requires video consultation for initial visit (asynchronous allowed for follow-ups).

States where compounding pharmacy shipment is restricted:

• Mississippi: Requires compounding pharmacies to register with state board before shipping to Mississippi residents. Most national compounding pharmacies are registered.
• Oregon: Requires patient to have established relationship with an Oregon-licensed provider before receiving compounded medications.

State availability changes; check the FormBlends intake for current coverage of your state before starting.

If you live in a restricted state, the traditional in-person pathway is your best option.

When you should NOT pursue a Zepbound prescription

The strongest argument against pursuing tirzepatide is when risks outweigh benefits. This section exists because most content on GLP-1 medications is written by companies selling access to those medications. We're one of those companies, and intellectual honesty requires acknowledging when our product isn't the right answer.

You should not pursue a Zepbound prescription if:

1. You have a personal or family history of medullary thyroid carcinoma or MEN2. This is an absolute contraindication. Tirzepatide carries a black box warning based on rodent studies showing thyroid C-cell tumors. The human risk is unknown but theoretically present. No weight-loss outcome justifies this risk.

2. You're pregnant, trying to conceive, or breastfeeding. Tirzepatide has not been studied in pregnancy. Animal studies show fetal harm. The FDA recommends discontinuing tirzepatide at least 2 months before attempting conception due to the long half-life. If you're breastfeeding, tirzepatide's presence in breast milk is unknown.

3. You have a history of severe pancreatitis. GLP-1 receptor agonists are associated with increased pancreatitis risk, though causality is debated. A 2023 meta-analysis (Azoulay et al., JAMA Internal Medicine) found a hazard ratio of 1.4 for pancreatitis in GLP-1 users vs controls. If you've had pancreatitis, the risk-benefit calculation changes. Some providers still prescribe with close monitoring. Others consider it too risky.

4. You have active suicidal ideation or severe depression. The FDA reviewed post-marketing reports of suicidal thoughts with GLP-1 medications in January 2024 and said its preliminary evaluation found no evidence of a causal link; the Zepbound label (revised 08/2026) carries no suicidal-ideation warning. Obesity itself is associated with depression, which confounds any signal. But if you're currently in crisis, starting a medication that might worsen mood is poor timing. Stabilize mental health first.

5. Your BMI is below 25 and you don't have metabolic disease. Using tirzepatide for cosmetic weight loss at normal BMI is outside standard of care. The medication has real risks (gallstones, gastroparesis, muscle loss during rapid weight loss). Those risks are justified when treating obesity-related health conditions. They're harder to justify for aesthetic goals.

6. You can't afford ongoing treatment and plan to stop after initial weight loss. Tirzepatide is not a cure. Weight regain after discontinuation is well-documented. The SURMOUNT-4 trial (Aronne et al., JAMA 2024) showed that participants switched to placebo after 36 weeks of tirzepatide regained 14% of their body weight over the following 52 weeks. If you can only afford 3-6 months of treatment, you'll likely regain most of the weight you lose. The yo-yo pattern may be worse for metabolic health than not losing weight at all.

7. You have untreated binge eating disorder. Tirzepatide suppresses appetite, which can mask binge eating disorder symptoms without treating the underlying psychological pattern. When the medication is discontinued, binge eating often returns worse than baseline. BED should be treated with therapy (CBT or DBT) before or alongside medication.

8. You're not willing to make dietary changes. The FDA label specifies tirzepatide "as an adjunct to a reduced-calorie diet and increased physical activity." You can lose weight on tirzepatide while eating maintenance calories (the medication creates a caloric deficit by suppressing appetite). But patients who combine medication with intentional dietary changes lose 20-25% of body weight vs 15-18% for medication alone (SURMOUNT-1 data). More importantly, patients who build sustainable eating habits during treatment are more likely to maintain weight loss if they discontinue medication.

The pattern we see in patients who regain weight quickly: they relied entirely on the medication for appetite suppression and didn't build new food relationships. When the medication stopped, old patterns returned.

What Zepbound costs in September 2026: list, savings card, LillyDirect, TrumpRx and the Medicare Bridge

The single biggest change since this guide was written is price. Every figure below was seen on the source named on September 5, 2026.

Route	Price	Who qualifies	Terms
List price	About $1,087 per month	Nobody should pay this	TrumpRx and GoodRx both show list near $1,087
Lilly savings card, plan covers Zepbound	$25 per fill	Commercial insurance with coverage; not Medicare, Medicaid, TRICARE or VA	Savings capped at $100 (1-month), $200 (2-month) or $300 (3-month fill); $1,300 a year; 13 fills; expires December 31, 2026
Lilly card, commercial plan does not cover Zepbound	$499 per month	Commercially insured, no coverage	Same card program, separate tier
LillyDirect self-pay, vial or KwikPen	$299 (2.5 mg), $399 (5 mg), $449 (7.5, 10, 12.5 and 15 mg)	Anyone with a valid prescription, insured or not	Refill within 45 days or the price is $499 (7.5 mg) or $699 (10 to 15 mg); free home delivery or pickup at Walmart pharmacies
TrumpRx	$299 per month	Self-pay	Listed as the entry price against a $1,087 original price; no as-of date on the page
GoodRx, Zepbound KwikPen	From $299	Self-pay at major chains	Coupon price mirrors LillyDirect
Medicare GLP-1 Bridge	$50 per month copay	Part D enrollees meeting BMI criteria, with prior authorization	July 1, 2026 to December 31, 2027; Zepbound KwikPen, Wegovy pen and pill, Foundayo; spending sits outside the $2,100 Part D cap

The Walmart pickup option dates from October 29, 2025, when LillyDirect and Walmart launched retail pickup of Zepbound vials at nearly 4,600 pharmacies at $349 and $499; Lilly has since cut the ladder to $299, $399 and $449. Two practical notes: the 2.5 mg dose is a starting dose, not a maintenance dose, so budget for the $399 and $449 tiers, and the 45-day refill rule is the difference between $449 and $699 at the higher doses.

Do you need a prescription for Zepbound? Yes, and here is the fastest legal route

Zepbound is a prescription-only medicine in every form: single-dose pen, vial and KwikPen. There is no over-the-counter version and no legal way to buy it without a prescriber's order. Compounded tirzepatide also requires a prescription, and the FDA counted more than 730 adverse-event reports for compounded tirzepatide as of May 31, 2026, most of them outside the prescriber-and-pharmacy system this article describes. Anything sold without a prescription, or labeled for research use, is not Zepbound.

The fastest legal routes as of September 2026, in order of speed:

1. LillyDirect. Lilly's site connects you to an independent telehealth provider, and if a prescription is written it is routed to LillyDirect Pharmacy or a dispensing partner (Amazon Pharmacy, Fuze, Gifthealth or Walmart) for delivery or Walmart pickup at the self-pay prices above.
2. Walgreens Virtual Healthcare. A $49 video visit and $49 follow-ups, self-pay only, available in 28 states; Walgreens does not handle prior authorization, so this is a cash-pay route.
3. Your own primary care clinician or a telehealth platform, which can also run insurance and prior authorization.

The label sets who qualifies (Zepbound prescribing information, revised 08/2026, Section 1): adults with obesity, or adults with overweight plus at least one weight-related condition, alongside a reduced-calorie diet and increased activity, and adults with obesity and moderate to severe obstructive sleep apnea. The only contraindications in Section 4 are a personal or family history of medullary thyroid carcinoma or MEN 2, and a serious hypersensitivity to tirzepatide or an ingredient.

Prior authorization in 2026: the federal clock and what UnitedHealthcare now requires

Two things changed in prior authorization this year, and neither is an approval rate.

The clock. CMS-0057-F, the interoperability and prior authorization final rule, took effect for impacted payers in 2026: Medicare Advantage plans, Medicaid and CHIP fee-for-service and managed care plans must decide expedited requests within 72 hours and standard requests within seven calendar days, and must give a specific reason for a denial. Qualified health plan issuers on the exchanges are excluded from the timeframe requirement, and self-funded employer plans are not covered at all, so the 2 to 4 week waits described earlier in this article still apply to many commercial plans.

The diabetes gate at UnitedHealthcare. UnitedHealthcare's prior authorization policy for GLP-1 diabetes agents, effective July 1, 2026, requires an A1C of 6.5 percent or higher or a fasting glucose of 126 mg/dL or higher, issues 12-month authorizations, and excludes weight-loss use. That policy is aimed at Mounjaro and Ozempic prescribed to people without diabetes; it is a reminder that Zepbound, not Mounjaro, is the product to request when the diagnosis is obesity.

Step	What to send	Where the templates are
Initial request	BMI and weight history, weight-related conditions with codes, documented lifestyle attempts, labs, contraindication screen	Your plan's form
Denial	Read the specific reason (required for CMS-covered plans from 2026) and answer it point by point	Lilly's appeals guide and letter of medical necessity template on zepbound.lilly.com/access-coverage
Appeal	Lilly's own guide warns that multiple appeal submissions may be necessary; request a peer-to-peer review if the plan offers one	Same page; Lilly's coverage checker shows plan status by insurer
While waiting	LillyDirect self-pay at $299 to $449 a month bridges the gap and does not require insurance	lilly.com/lillydirect/zepbound

Compounded tirzepatide after the shortage ended (December 19, 2024)

The section above was written when tirzepatide was on the FDA shortage list. It is not any more, and the market that grew up around the shortage has changed in three ways.

Legal basis. Since December 19, 2024, compounded tirzepatide is available only as patient-specific compounding, where the prescriber documents a clinical reason the approved product does not meet. The compounding industry's lawsuit over the FDA's shortage determinations ended at the Fifth Circuit on August 27, 2026, in the FDA's favor.

Safety record. The FDA's public tally stood at more than 730 adverse-event reports for compounded tirzepatide and 990 for compounded semaglutide as of May 31, 2026, with dosing errors from vials and syringes a recurring theme.

Price. The cash gap that justified compounding has narrowed. Brand Zepbound is $299 to $449 a month through LillyDirect. Compounded tirzepatide, per the Compounded GLP-1 Price Index on September 3, 2026:

Compounded tirzepatide	Median	Range	Providers
Month 1 (2.5 mg)	$299	$149 to $470	14
Month 4 (5 mg)	$299	$179 to $627	11

At the median, compounded tirzepatide costs the same as the 2.5 mg LillyDirect tier and $100 to $150 less than the 5 mg and higher tiers. The trade is an FDA-approved product in a pen against a compounded vial you draw up yourself; the decision belongs with you and your prescriber, not with a price alone.

Label facts to get right: start dose, escalation, maintenance and contraindications (revised 08/2026)

Much of what circulates online about Zepbound dosing is loose. The prescribing information revised in August 2026 says the following, and your prescriber will work from it.

Label item	What it says	Section
Starting dose	2.5 mg once weekly for 4 weeks; 2.5 mg is not approved as a maintenance dose	2.1
Escalation	Increase in 2.5 mg steps after at least 4 weeks at the current dose	2.1
Maintenance	5, 10 or 15 mg for weight management; 10 or 15 mg for obstructive sleep apnea; maximum 15 mg	2.2
Presentations	Single-dose pen or vial 2.5 to 15 mg; the multi-dose vial and single-patient-use KwikPen each hold 4 doses	3
Contraindications	Personal or family history of medullary thyroid carcinoma or MEN 2; serious hypersensitivity to tirzepatide or any ingredient	4
Indications	Adults with obesity, or overweight with a weight-related condition, to reduce excess body weight and maintain the reduction long term; adults with obesity and moderate to severe OSA	1

Two implications for the prescription itself. A prescription written for 2.5 mg as a long-term dose is off-label, and the KwikPen's 4-dose design means one KwikPen is one month, which is how the LillyDirect price ladder is quoted.

FAQ

How do I get a prescription for Zepbound?

Schedule a consultation with a licensed provider (in-person, telehealth, or weight-loss clinic), meet FDA eligibility criteria (BMI ≥30 or ≥27 with comorbidities), complete medical screening for contraindications, and receive a prescription if approved. Telehealth platforms offer the fastest pathway (48-72 hours). Traditional providers take 2-4 weeks.

Can I get Zepbound without seeing a doctor in person?

Yes. Telehealth platforms allow you to consult with a licensed provider via video or asynchronous messaging and receive a prescription without an in-person visit. The provider must be licensed in your state and must establish a provider-patient relationship through the telehealth consultation.

What BMI do you need for Zepbound?

FDA approval requires BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (diabetes, hypertension, high cholesterol, or sleep apnea). Some providers prescribe off-label at BMI 25-26.9, but this is less common and typically requires documented metabolic disease.

Will my insurance cover Zepbound?

Coverage varies by plan, and insurers do not publish approval rates. Common denial reasons include insufficient BMI documentation, lack of previous weight-loss attempts, or formulary restrictions. If denied, you can appeal using Lilly's appeals guide and letter of medical necessity template, pay the LillyDirect self-pay price of $299 to $449 a month, or pay cash for compounded tirzepatide (month-1 median $299, September 3, 2026).

How much does Zepbound cost without insurance?

As of September 5, 2026, brand-name Zepbound lists at about $1,087 a month, but nobody needs to pay that: LillyDirect sells the vial or KwikPen for $299 (2.5 mg), $399 (5 mg) or $449 (7.5 to 15 mg) when you refill within 45 days, and commercially insured patients whose plan excludes Zepbound pay $499 through the Lilly card. Compounded tirzepatide had a month-1 median of $299 (range $149 to $470) across 14 telehealth providers on September 3, 2026.

What's the difference between Zepbound and compounded tirzepatide?

Both contain the same active ingredient (tirzepatide) at the same doses. Zepbound is FDA-approved and manufactured by Eli Lilly in pre-filled autoinjector pens. Compounded tirzepatide is prepared by state-licensed compounding pharmacies in multi-dose vials and is not FDA-approved. Since the shortage ended on December 19, 2024, compounded tirzepatide is legal only as patient-specific compounding with a documented clinical reason.

How long does it take to get a Zepbound prescription?

Telehealth platforms: 2-7 days from intake to prescription. Traditional in-person providers: 2-4 weeks including appointment scheduling and lab work. Insurance prior authorization adds 1-4 weeks if required.

Can my primary care doctor prescribe Zepbound?

Yes, if they're willing. Zepbound doesn't require a specialist. Many PCPs prescribe GLP-1 medications for weight loss. Some prefer to refer to endocrinology or obesity medicine specialists. Ask your PCP directly about their comfort level with prescribing tirzepatide.

Do I need lab work before getting Zepbound?

Most providers require baseline labs (A1C, comprehensive metabolic panel, lipid panel, TSH) before prescribing. Some telehealth platforms accept labs done within the past 6 months. If you don't have recent labs, the provider will order them, which adds 3-7 days to the timeline.

Can I get Zepbound if I have diabetes?

Yes. Tirzepatide is FDA-approved for type 2 diabetes under the brand name Mounjaro (same drug, different indication). If you have diabetes and obesity, your provider will likely prescribe Mounjaro rather than Zepbound, since insurance coverage is better for the diabetes indication.

What if I don't meet the BMI requirement?

If your BMI is below 27, you'll need a provider willing to prescribe off-label. Traditional in-person providers have more discretion than telehealth platforms. Some providers will prescribe at BMI 25-26.9 if you have documented insulin resistance or metabolic syndrome. Below BMI 25, standard-of-care prescribing is rare.

Can I use a Zepbound savings card with compounded tirzepatide?

No. Manufacturer savings cards only apply to brand-name prescriptions filled at retail pharmacies. Compounded medications are not eligible for manufacturer coupons or insurance coverage.

How do I know if a telehealth platform is legitimate?

Check that the platform uses licensed providers in your state, requires medical screening before prescribing, and partners with licensed pharmacies (retail or compounding). Red flags include: no provider consultation required, prescribing without asking about contraindications, no U.S. pharmacy named on the label, or prices far below the September 2026 index range of $149 to $470 for a first month of compounded tirzepatide.

What happens if the FDA removes tirzepatide from the shortage list?

The FDA already did, on December 19, 2024, and the compounders' court challenge failed at the Fifth Circuit on August 27, 2026. Since then, 503A pharmacies may compound tirzepatide only for an individual patient with a prescriber-documented clinical need, 503B facilities may not make copies of Zepbound, and brand Zepbound is available self-pay at $299 to $449 a month through LillyDirect.

Can I switch from Zepbound to compounded tirzepatide?

Yes. The active ingredient and dosing are the same. The main difference is delivery method (autoinjector pen vs manual injection from vial). Your provider can write a new prescription for compounded tirzepatide at your current dose. No titration restart is needed.

Can you get Zepbound without a doctor's prescription?

No. Zepbound is prescription-only in every form, and compounded tirzepatide also requires a prescription. Anything sold without a prescriber's order, including vials labeled for research use, is not Zepbound and is not covered by the FDA's oversight of pharmacies; the FDA had logged more than 730 adverse-event reports for compounded tirzepatide as of May 31, 2026. The fastest legal routes are LillyDirect's telehealth referral, a $49 Walgreens Virtual Healthcare visit, or your own clinician.

How much is Zepbound with the savings card?

As of September 5, 2026, commercially insured patients whose plan covers Zepbound pay as little as $25 per fill, with savings capped at $100, $200 or $300 for a 1, 2 or 3-month fill, $1,300 a year and 13 fills; the card expires December 31, 2026. Commercially insured patients whose plan does not cover Zepbound pay $499 a month. Medicare, Medicaid, TRICARE and VA patients cannot use the card (zepbound.lilly.com).

Does Medicare cover Zepbound?

Partly, and only recently. From July 1, 2026 through December 31, 2027, the Medicare GLP-1 Bridge lets Part D enrollees who meet BMI criteria get the Zepbound KwikPen, Wegovy pen and pill, or Foundayo for a $50 monthly copay with prior authorization; that spending sits outside the $2,100 Part D out-of-pocket cap (healthinsurance.org, 2026). Medicare patients cannot use the Lilly savings card.

Can I pick up Zepbound at Walmart?

Yes. Since November 2025, prescriptions routed through LillyDirect can be filled for pickup at nearly 4,600 Walmart pharmacies, and Lilly's September 2026 pricing applies: $299 for 2.5 mg, $399 for 5 mg and $449 for 7.5 to 15 mg per month for the vial or KwikPen when you refill within 45 days. Any valid on-label prescription qualifies regardless of insurance status (Walmart and LillyDirect announcement, October 29, 2025; lilly.com).

Related guides

• How to Get a Tirzepatide Prescription: The Complete Eligibility, Provider, and Access Pathway for 2026
• How to Get Compound Tirzepatide in 2026: The Five-Step Protocol from Eligibility to First Dose
• How to Get a Semaglutide Prescription: The Complete 2026 Provider-to-Pharmacy Pathway
• How to Get a Wegovy Prescription in 2026: Eligibility, Provider Options, and What to Expect at Your Appointment
• How to Get a Prescription for Wegovy in 2026: The Complete Eligibility and Provider Path
• How to Get Prescribed Zepbound: The Complete Eligibility, Lab, and Access Protocol for 2026
• Tool: dosage calculator

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
3. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
4. Azoulay L et al. Incretin-Based Drugs and the Risk of Pancreatitis. JAMA Internal Medicine. 2023.
5. U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss, adverse-event counts as of May 31, 2026. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
6. U.S. Food and Drug Administration. Clarification of policies for compounders as national GLP-1 supply begins to stabilize (tirzepatide shortage resolved), December 19, 2024. https://www.fda.gov/media/185577/download
7. Eli Lilly. LillyDirect Zepbound self-pay pricing (CMAT-05333 08/2026). https://www.lilly.com/lillydirect/zepbound
8. American Association of Clinical Endocrinology. Clinical Practice Guideline for the Pharmacological Management of Obesity. 2024.
9. Garvey WT et al. American Association of Clinical Endocrinology and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2024.
10. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
11. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
12. Centers for Medicare & Medicaid Services. CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F) fact sheet. https://www.cms.gov/newsroom/fact-sheets/cms-interoperability-and-prior-authorization-final-rule-cms-0057-f
13. National Association of Boards of Pharmacy. State Telehealth Prescribing Regulations. Updated March 2026.
14. Eli Lilly. Zepbound (tirzepatide) prescribing information, revised 08/2026. https://pi.lilly.com/us/zepbound-uspi.pdf
15. Eli Lilly. Zepbound coverage and savings card terms, seen September 5, 2026. https://zepbound.lilly.com/coverage-savings
16. Eli Lilly. Zepbound access and coverage: appeals guide and letter of medical necessity, seen September 5, 2026. https://zepbound.lilly.com/access-coverage
17. TrumpRx. Zepbound, Wegovy and Ozempic self-pay listings, seen September 5, 2026. https://trumprx.gov
18. healthinsurance.org. Does health insurance cover drugs used for weight loss? (Medicare GLP-1 Bridge), 2026. https://www.healthinsurance.org/faqs/does-health-insurance-cover-drugs-used-for-weight-loss-such-as-ozempic-wegovy-mounjaro-and-zepbound/
19. UnitedHealthcare. Prior authorization notification: diabetes agents, GLP-1 receptor agonists, effective July 1, 2026. https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/a-g/PA-Notification-Diabetes-Agents-GLP1-Receptor-Agonists.pdf
20. FormBlends. Compounded GLP-1 Price Index, as of September 3, 2026. https://formblends.com/feeds/glp1-prices.json
21. Walmart. LillyDirect and Walmart Pharmacy launch first retail pick-up option for Zepbound, October 29, 2025. https://corporate.walmart.com/news/2025/10/29/lillydirect-and-walmart-pharmacy-launch-first-retail-pick-up-option-with-direct-to-consumer-pricing-for-zepbound
22. Walgreens Virtual Healthcare. Zepbound weight-loss visits, seen September 5, 2026. https://www.walgreens.com/topic/virtual-healthcare/weight-loss/zepbound.jsp

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Wegovy, and Ozempic are registered trademarks of their respective manufacturers (Eli Lilly and Company, Novo Nordisk). Pepcid, Prilosec, Nexium, and other medication names are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.